FMP
Kymera Therapeutics, Inc.
KYMR
NASDAQ
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
34.37 USD
0.92 (2.68%)
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
34.03M
72.83M
46.83M
78.59M
47.07M
57.9M
71.22M
87.61M
107.76M
132.56M
-
114
-35.71
67.84
-40.11
23.01
23.01
23.01
23.01
88.13M
-128.95M
-153.09M
-102.83M
-194.5M
-34.74M
-42.73M
-52.57M
-64.66M
-79.53M
258.95
-177.05
-326.92
-130.84
-413.2
-60
-60
-60
-60
-9.1M
-1.6M
-2.84M
-34.48M
-12.84M
-12.29M
-15.12M
-18.59M
-22.87M
-28.13M
-26.73
-2.19
-6.06
-43.87
-27.27
-21.22
-21.22
-21.22
-21.22
79.03M
-130.54M
-155.92M
-137.31M
-207.34M
-47.03M
-57.85M
-71.16M
-87.53M
-107.67M
34.37
75.04M
4.09
4.09
87.76M
2.58B
2.67B
3.29
96.71
14.25
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
34.03M
72.83M
46.83M
78.59M
47.07M
57.9M
71.22M
87.61M
107.76M
132.56M
88.13M
-128.95M
-153.09M
-102.83M
-194.5M
-34.74M
-42.73M
-52.57M
-64.66M
-79.53M
-9.1M
-1.6M
-2.84M
-34.48M
-12.84M
-12.29M
-15.12M
-18.59M
-22.87M
-28.13M
79.03M
-130.54M
-155.92M
-137.31M
-207.34M
-47.03M
-57.85M
-71.16M
-87.53M
-107.67M
14.25
14.25
14.25
14.25
14.25
-41.16M
-44.32M
-47.71M
-51.37M
-55.3M
-239.86M
14.25
-109.82M
-896.25M
-460.34M
-700.2M
-32.49M
-667.71M
75.04M
-8.9
-8.9 4.862%